OBJECTIVES: Cross-sectional research designs are often employed to answer questions in a timely, cost-effective manner. A common situation is nonresponse, where missing or incomplete data may introduce bias when only the complete data are analyzed. In conducting a survey of type-2 Diabetes Mellitus (T2DM) patients with and without symptoms of ADHD, HbA1c values, a primary measure of diabetes control, were obtained from 314 of 567 (55%) cases. Classifi cation trees, a data-mining tool useful for predicting categorical responses, were used to examine the covariate related pattern of the missing data. METHODS: The study design utilized an internet-based panel of 567 T2DM cases that consented to participate in a survey assessing the level to which ADHD symptoms, when present, impacted the ability to manage HbA1c and other diabetes symptoms. In addition to de-identifi ed demographic data, respondents were asked to provide information on diabetes self-care, HbA1c values, ADHD symptoms, and health care resource utilization. Classifi cation trees were used to develop a predictive model for the occurrence of missing HbA1c values. RESULTS: A classifi cation tree analysis revealed that the diabetes self-care score (SCI-R total score: n 567, mean 62.3, SD 15.9) was an important predictor of missing HbA1c. Those respondents who had diabetes self-care scores below 51 were less likely to have provided an HbA1c. A high SCI-R total score indicates a high level of self-care, and the SCI-R total score has been found to correlate negatively with HbA1c, suggesting that better self-care is associated with better glycemic control. CONCLUSIONS: Classifi cation trees can be useful in understanding the structure of missing data. This understanding is a fi rst step in an analysis of a survey and can infl uence decisions on the need for imputation of missing data and the imputation method. Simulation studies can be used to estimate or forecast drug effectiveness in a representative sample by translating a survival benefi t established in a clinical trial. The methods of this translation have not been described. The present study describes how the translation is operationalized using a combination of clinical trial and observational data. We simulate the population impact of docetaxel (D), the fi rst chemotherapy agent to demonstrate a survival benefi t in patients with hormone refractory prostate cancer (HRPC). The survival benefi t of D was established in the TAX327 trial however it is unclear how the benefi t may translate to a heterogeneous population of patients. METHODS: A combination of TAX327 trial data and SEER-Medicare (SM) data were used. In pts age 69 and randomized to D (every 3 weeks, D3P) or mitoxantrone (M), trial data showed a survival benefi t for D. Accordingly, 3,515 SM pts age 69 , diagnosed with M1 PC between 1994 and 2002, and receiving only androgen deprivation therapy (ADT) were selected. Graphical plots and likelihood ratio tests were used to identify the best-fi tting parametric survival functions for D3P, M, and SM patients. Candidate (selected) curves included: gamma, lognormal, weibull, exponential, and polynomial (log-logistic) functions. The survival benefi t function from the trial was calculated using parametric curves fi tted to D3P and M data and subsequently imposed on the SM survival curve. The simulated benefi t was assessed in 3 scenarios depending on the assumed time of chemotherapy initiation: at diagnosis of M1 PC, at 12 mos post-diagnosis, and at 24 mos postdiagnosis. The simulated benefi t in the SM sample was examined following adjustments for sample heterogeneity due to demographic, clinical, and ecologic factors. RESULTS: We fi nd that the simulated survival benefi t is sensitive to adjustments for sample heterogeneity and also is sensitive to assumptions regarding the time of chemotherapy initiation.
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Cao Z 1 , Durden ED 2 , Mark TL 2 1 The Healthcare Business of Thompson Reuters, Cambridge, MA, USA, 2 The Healthcare Business of Thompson Reuters, Washington, DC, USA OBJECTIVES: The objective of this paper is to empirically compare inverse probability of treatment weights (IPTW) adjustment with propensity score matching method using the Thomson Reuter's MarketScan commercial claims database. METHODS: There are three treatment groups in this study: treatment with nasal corticosteroids, with nasal antihistamines and combination treatment. We applied both the IPTW method and the traditional matching by propensity scores. In the propensity score matching, we used nearest neighbor method to match the patients in the nasal corticosteroids group with those in the antihistamines group. A second matching was implemented between the nasal corticosteroids and combination treatment group. Alternatively, a generalized multinomial logit model was estimated to obtain the propensity scores. The conditional probabilities of receiving the particular type of treatment given the pre-treatment factors were used as the generalized propensity scores. A propensity score weight, also referred to as IPTW, was calculated for each case in each treatment group as the inverse of the generalized propensity score. Descriptive Statistics were obtained and difference between the groups tested after applying IPTW and propensity score matching. Logistics regressions of probability of any respiratory infection were estimated using both methods. We compared the point estimates and standard errors of treatment effect using two methods. RESULTS: Both IPTW and propensity score matching methods reduced the differences in the pre-treatment factors across treatment groups. In the multivariate regressions, patients treated with corticosteroids were found to have signifi cantly lower probability to have any respiratory infection compared with those treated with intranasal antihistamine when using the propensity score matched sample. However, using the IPTW method, we found that the treatment effects had larger standard errors and were not signifi cant. CONCLU-SIONS: IPTW is less time-consuming compared with traditional matching procedure. However, the IPTW weighting method generates bigger standard errors compared with the traditional matching method. Pharmaceutical Services LLC, Raritan, NJ, USA OBJECTIVES: Suitable long-term data are rarely available when reimbursement decisions are made for T2DM drugs. If properly constructed and applied, economic simulation models can be useful tools for decision-making. To provide confi dence that model results refl ect reality, the ability of these models to replicate results from actual clinical studies should be assessed with formal validity tests. The objective of this study was to assess the validity of a new economic simulation model of T2DM. METHODS: The economic simulation model of T2DM is a stochastic, micro-simulation model that consists of Markov health states representing the development and consequences of key micro-and macro-vascular diabetes complications. Model predictions for 82 outcomes covering 16 different patient populations from six published outcomes studies were generated by replicating the health and demographic profi les of each patient population, applying the study inclusion/exclusion criteria and treatments, and then simulating outcomes for an equivalent length of time. Where published data were incomplete for a study, the most suitable data from other studies were used. Predicted outcomes were plotted against observed outcomes to assess model fi t, as all points would lie on the unit line when the predicted and observed values match exactly. The predictive fi t was assessed both overall and separately by whether the source data were or were not used in model construction. RESULTS: The best-fi tting line through the cluster plot of predicted versus actual outcomes emanated from the origin with slope 1.07. The resulting R2 was 0.95. The model predicted outcomes for internal and external studies equally well, with R2 values of 0.95 and 0.97, respectively. CONCLUSIONS: Results suggest the model corresponds well with actual clinical data, even considering studies not used in model construction. Though model-based results must always be interpreted cautiously, the model can be considered a useful decision-making tool. The recalibrated model maintained the indirect benefi t of infant vaccination to the older, unvaccinated populations demonstrating 35% fewer IPD cases in the 65 year age group fi ve years after PCV7 introduction. CONCLUSIONS: The improved epidemiologic model simulates the observed US surveillance data to date. By modifying key input parameters, this model can be used to simulate the impact of various vaccination strategies in the US and other developed countries.
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